Suvecaltamide - Jazz Pharmaceuticals
Alternative Names: CX 8998; JZP-385Latest Information Update: 08 May 2024
At a glance
- Originator Cavion
- Developer Jazz Pharmaceuticals plc
- Class Acetamides; Antipsychotics; Ethers; Fluorocarbons; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action T type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Essential tremor
- No development reported Epilepsy
- Discontinued Neuropathic pain
Most Recent Events
- 02 May 2024 Jazz Pharmaceuticals completes enrolment in its phase II trial in Essential tremor (In adults, In the elderly) in Poland, Germany, Spain (PO) (EudraCT-2020-002463-61)
- 23 Feb 2022 Discontinued - Preclinical for Neuropathic pain in USA (unspecified route)
- 23 Feb 2022 No development reported - Phase-II for Epilepsy (In adolescents, In adults) in USA (unspecified route)